Medical Lawyers in NYC Guide on Medical Device Approvals

If your device is Class II, you will likely use the 510(k) pathway, which is faster and less expensive than PMA but requires demonstrating substantial equivalence to a predicate device already on the market. Selecting the right predicate is crucial because it anchors your entire submission. The predicate must be legally marketed, must have the same intended use or a similar technological characteristic, and must not be subject to any FDA enforcement action. In practice, predicate selection disputes frequently arise during FDA review, and the agency may reject your chosen predicate if it believes the comparison is not appropriate. Working with experienced defective medical devices counsel early ensures your predicate strategy is defensible and your submission timeline stays on track.

Class III devices require PMA, a more demanding process that includes clinical trial data, manufacturing quality systems, and labeling review. The PMA process typically takes 180 days for standard review or 90 days for priority review, though complex submissions often exceed these timelines. Your submission must demonstrate that the device is safe and effective for its intended use, supported by adequate clinical evidence. The FDA may issue a Complete Response Letter (CRL) requesting additional data or modifications, which resets the review clock. From a practitioner's perspective, anticipating potential FDA questions during PMA preparation and building robust clinical data packages upfront reduces the likelihood of CRL delays.

MDR reporting obligations are non-negotiable. You must report deaths within 30 days and serious injuries within 30 days of becoming aware of the event. Many companies underestimate the scope of what constitutes a reportable event or delay reporting pending internal investigation, both of which create compliance violations. The FDA maintains a public database of adverse events (MAUDE), and unreported or delayed reports can expose your company to enforcement action. When a recall becomes necessary, the FDA classifies it as Class I (serious risk of injury or death), Class II (less serious adverse health consequences), or Class III (unlikely to cause adverse health consequences). Class I recalls often trigger litigation, regulatory scrutiny, and reputational damage.

In New York, product liability claims involving medical devices are governed by strict liability, negligence, and breach of warranty theories. New York courts recognize that FDA approval does not shield a manufacturer from liability if the device is defectively designed, manufactured, or inadequately warned. The New York Court of Appeals has held that a manufacturer can be liable even if a device complies with FDA standards if the device is unreasonably dangerous or the warnings are inadequate. This means that regulatory compliance, while necessary, is not sufficient protection in civil litigation. Understanding New York's product liability framework is critical when designing compliance strategies and evaluating insurance coverage.

If your device requires clinical data, the design of your clinical trial and the endpoints you select will determine whether the FDA finds your evidence adequate. Poorly designed trials or weak endpoints can result in CRL or PMA denial. Conversely, robust, well-designed clinical data can accelerate approval and provide strong litigation defensibility. The FDA provides guidance documents on specific device types, and consulting these early in development ensures your trial design aligns with regulatory expectations. Regulatory counsel should review your clinical protocol before enrollment begins to identify potential FDA concerns and adjust your strategy accordingly.

As you move forward with your device approval strategy, consider whether your current regulatory pathway remains optimal as your device evolves, whether your post-market surveillance plan adequately captures safety signals, and how your approval documentation will support your defense in product liability litigation. These questions require integrated legal and regulatory judgment, not merely compliance checklist completion.